No profile data available.
Anbio Biotechnology (NNNN) is a healthcare company in the chemical laboratory testing equipment industry, based in Frankfurt am Main, Germany, with about 27 full-time employees.
It reported revenue of $8.19 million for fiscal year 2024, up 21.9% from fiscal year 2023, and net income of $2.37 million. European Union was its largest region in fiscal year 2025, with 60% of revenue. Its market capitalization was $204.53 million as of October 9, 2026.
Figures from company filings and market data; latest fiscal year ended December 31, 2024; market data as of October 9, 2026.
Anbio Biotechnology provides in vitro diagnostics (IVD) products in the European Union, the Asia Pacific, North America, South America, and internationally.
Anbio Biotechnology reported $8.19 million in revenue for fiscal year 2024, up 21.9% from $6.71 million in fiscal year 2023.
European Union: 60% of revenue by region in fiscal year 2025, followed by Asia Pacific (18%).
$204.53 million as of October 9, 2026.
Listed companies of a similar size in the same industry (chemical laboratory testing equipment) include DexCom, Inc. (DXCM), Senseonics Holdings, Inc. (SENS), OraSure Technologies, Inc. (OSUR), DarioHealth Corp. (DRIO).